Complement regulatory protein Crry/p65 costimulation expands natural treg cells with enhanced suppressive properties in proteoglycan-induced arthritis.

OBJECTIVE To investigate the costimulatory role of Crry/p65 (Crry), a membrane complement regulatory protein, on the expansion and function of natural Treg cells and their ability to ameliorate proteoglycan-induced arthritis (PGIA), an animal model of inflammatory arthritis in which the role of natural Treg cells is not well established. METHODS CD4+CD25+ natural Treg cells from BALB/c mice were activated in vitro and costimulated by Crry. The expanded cells were phenotypically characterized, and their suppressive effect on T cell proliferation was assayed in vitro. The potential prophylactic and therapeutic effects of this population versus those of natural Treg cells in PGIA were studied. The clinical score, histology, the antigen-specific isotype antibody pattern, in vitro T cell responses, and the presence of Treg cells in the paws were studied. RESULTS Crry costimulation enhanced the in vitro expansion of natural Treg cells while maintaining their phenotypic and suppressive properties. Crry-expanded Treg cells had stronger suppressive properties in vivo and a longer ameliorating effect in the PGIA model than did natural Treg cells. Crry-expanded Treg cells suppressed T cell- and B cell-dependent responses in PGIA, changing the pathogenic antibody isotype pattern and decreasing antigen-dependent secretion of cytokines, including interferon-γ, interleukin-12 (IL-12), and IL-17. Increased FoxP3 expression was detected in the paws of mice transferred with Crry-expanded Treg cells. CONCLUSION Crry-mediated costimulation facilitates in vitro expansion of natural Treg cells while maintaining their suppressive properties in vitro and in vivo in the PGIA model. These results highlight the potential of the complement regulatory protein Crry to costimulate and expand natural Treg cells capable of suppressing disease in an animal model of chronic inflammatory arthritis.

[1]  Graham M Lord,et al.  Complement regulator CD46 temporally regulates cytokine production by conventional and unconventional T cells , 2010, Nature Immunology.

[2]  T. Nomura,et al.  Complement drives Th17 cell differentiation and triggers autoimmune arthritis , 2010, The Journal of experimental medicine.

[3]  W. van Eden,et al.  Cartilage proteoglycan aggrecan epitopes induce proinflammatory autoreactive T-cell responses in rheumatoid arthritis and osteoarthritis , 2009, Annals of the rheumatic diseases.

[4]  T. Glant,et al.  IFN-γ Regulates the Requirement for IL-17 in Proteoglycan-Induced Arthritis , 2009, The Journal of Immunology.

[5]  C. Benoist,et al.  Foxp3+ regulatory T cells: differentiation, specification, subphenotypes , 2009, Nature Immunology.

[6]  T. Glant,et al.  Age-related changes in arthritis susceptibility and severity in a murine model of rheumatoid arthritis , 2009, Immunity & Ageing.

[7]  E. Shevach.  Mechanisms of foxp3+ T regulatory cell-mediated suppression. , 2009, Immunity.

[8]  A. Rudensky,et al.  Control of regulatory T cell lineage commitment and maintenance. , 2009, Immunity.

[9]  James L Riley,et al.  Human T regulatory cell therapy: take a billion or so and call me in the morning. , 2009, Immunity.

[10]  O. Leavy.  Regulatory T cells: Taking the right route , 2009, Nature Reviews Immunology.

[11]  H. Bu,et al.  Mouse CD4+ CD25+ T regulatory cells are protected from autologous complement mediated injury by Crry and CD59. , 2009, Biochemical and biophysical research communications.

[12]  R. Jessberger,et al.  Regulatory T cells sequentially migrate from inflamed tissues to draining lymph nodes to suppress the alloimmune response. , 2009, Immunity.

[13]  Thomas Korn,et al.  IL-17 and Th17 Cells. , 2009, Annual review of immunology.

[14]  T. Glant,et al.  Th1/Th17 polarization and acquisition of an arthritogenic phenotype in arthritis-susceptible BALB/c, but not in MHC-matched, arthritis-resistant DBA/2 mice , 2009, International immunology.

[15]  W. van Eden,et al.  Oral or Nasal Antigen Induces Regulatory T Cells That Suppress Arthritis and Proliferation of Arthritogenic T Cells in Joint Draining Lymph Nodes , 2008, The Journal of Immunology.

[16]  Y. Iwakura,et al.  Development of Proteoglycan-Induced Arthritis Is Independent of IL-171 , 2008, The Journal of Immunology.

[17]  L. Boon,et al.  Autologous bone marrow transplantation in autoimmune arthritis restores immune homeostasis through CD4+CD25+Foxp3+ regulatory T cells. , 2008, Blood.

[18]  U. Dianzani,et al.  CD4+ICOS+ T lymphocytes inhibit T cell activation 'in vitro' and attenuate autoimmune encephalitis 'in vivo'. , 2008, International immunology.

[19]  P. Portolés,et al.  The renaissance of T regulatory cells: Looking for markers in a haystack , 2007 .

[20]  V. Kuchroo,et al.  TH-17 cells in the circle of immunity and autoimmunity , 2007, Nature Immunology.

[21]  W. van Eden,et al.  Increased arthritis susceptibility in cartilage proteoglycan-specific T cell receptor-transgenic mice. , 2006, Arthritis and rheumatism.

[22]  C. June,et al.  Clinical application of expanded CD4+25+ cells. , 2006, Seminars in immunology.

[23]  J. Madrenas,et al.  Complement regulatory protein Crry/p65‐mediated signaling in T lymphocytes: role of its cytoplasmic domain and partitioning into lipid rafts , 2005, Journal of leukocyte biology.

[24]  M. Karim,et al.  CD25+CD4+ regulatory T cells generated by exposure to a model protein antigen prevent allograft rejection: antigen-specific reactivation in vivo is critical for bystander regulation. , 2005, Blood.

[25]  A. Rudensky,et al.  Regulatory T cell lineage specification by the forkhead transcription factor foxp3. , 2005, Immunity.

[26]  T. Ley,et al.  Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. , 2004, Blood.

[27]  T. Ley,et al.  Human T regulatory cells can use the perforin pathway to cause autologous target cell death. , 2004, Immunity.

[28]  T. Glant,et al.  Achievement of a synergistic adjuvant effect on arthritis induction by activation of innate immunity and forcing the immune response toward the Th1 phenotype. , 2004, Arthritis and rheumatism.

[29]  S. Sakaguchi.  Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. , 2004, Annual review of immunology.

[30]  Andreas Radbruch,et al.  Predominant cellular immune response to the cartilage autoantigenic G1 aggrecan in ankylosing spondylitis and rheumatoid arthritis. , 2003, Rheumatology.

[31]  K. Murphy,et al.  Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype , 2003, Nature.

[32]  K. Mikecz,et al.  CD4+CD25+ immunoregulatory T cells may not be involved in controlling autoimmune arthritis , 2003, Arthritis research & therapy.

[33]  T. Glant,et al.  Proteoglycan-induced arthritis: immune regulation, cellular mechanisms, and genetics. , 2003, Critical reviews in immunology.

[34]  P. Scott,et al.  Maintenance of IL‐12‐responsive CD4+ T cells during a Th2 response in Leishmania major‐infected mice , 2000, European journal of immunology.

[35]  P. Portolés,et al.  Crry/p65, a Membrane Complement Regulatory Protein, Has Costimulatory Properties on Mouse T Cells1 , 2000, The Journal of Immunology.

[36]  A. Poole,et al.  Isolation and characteristics of autoreactive T cells specific to aggrecan G1 domain from rheumatoid arthritis patients , 2000, Cell Research.

[37]  Ethan M. Shevach,et al.  Suppressor Effector Function of CD4+CD25+ Immunoregulatory T Cells Is Antigen Nonspecific , 2000, The Journal of Immunology.

[38]  P. Tao,et al.  Proteoglycan (aggrecan)-induced arthritis in BALB/c mice is a Th1-type disease regulated by Th2 cytokines. , 1999, Journal of immunology.

[39]  J. Esdaile,et al.  Immune responses to cartilage link protein and the G1 domain of proteoglycan aggrecan in patients with osteoarthritis. , 1999, Arthritis and rheumatism.

[40]  G R Burmester,et al.  Mononuclear phagocytes and rheumatoid synovitis. Mastermind or workhorse in arthritis? , 1997, Arthritis and rheumatism.

[41]  C. Hsieh,et al.  T cell genetic background determines default T helper phenotype development in vitro , 1995, The Journal of experimental medicine.

[42]  C. Janeway,et al.  Monoclonal antibodies to murine CD3 epsilon define distinct epitopes, one of which may interact with CD4 during T cell activation. , 1989, Journal of immunology.

[43]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[44]  F. Bach,et al.  A miniaturized mouse mixed leukocyte culture in serum-free and mouse serum supplemented media. , 1973, Journal of immunological methods.